Top

Published in:

01-06-2012 | Review Article

How to manage HIV-infected patients with chronic kidney disease in the HAART era

Authors: Minoru Ando, Ken Tsuchiya, Kosaku Nitta

Published in: Clinical and Experimental Nephrology | Issue 3/2012

Abstract

As human immunodeficiency virus (HIV)-infected patients now live longer while receiving highly active antiretroviral therapy (HAART), chronic kidney disease (CKD) has emerged as a significant cause of morbidity and mortality among urban HIV population. Risk factors associated with CKD in such HIV-infected population include aging, hypertension, diabetes mellitus, co-infection with hepatitis C virus, low CD4 cell count, and high HIV viral load. Clinical experience has shown that HIV-infected individuals often have one or more concurrent risk factors for CKD. The cumulative effect of multiple risk factors on the development of CKD should be noted in this population. Glomerular disease directly related to HIV infection, so-called HIV-associated nephropathy, remains an important cause of CKD among limited HIV population of African descent. The impact of exposure to nephrotoxic antiretroviral agents on the development of kidney disease is both an old and a new concern. In particular, the association of tenofovir with kidney disease has been an area of great interest. The findings regarding tenofovir’s adverse effect on long-term kidney function vary among studies. Early identification and treatment of kidney disease is imperative for reducing the burden of patients requiring dialysis in HIV-infected populations. Periodic monitoring of urinary albumin excretion, tubular parameters such as low-molecular-weight proteinuria, and the estimated glomerular filtration rate may be useful for early diagnosis of patients at risk for incident CKD. This review focuses on recent developments in epidemiology, risk factors, identification, estimation, and management of CKD in HIV-infected population in the HAART era.

Lohse N, Hansen AB, Pedersen G, Kronborg G, Gerstoft J, Sorensen HT, et al. Survival of persons with and without HIV infection in Denmark, 1995–2005. Ann Intern Med. 2007;146:87–95.PubMed

Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d’Arminio Monforte A, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet. 2003;362:22–9.PubMedCrossRef

Gupta SK, Eustace JA, Winston JA, Boydstun II, Ahuja TS, Rodriguez RA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2005;40:1559–85.PubMedCrossRef

Eggers PW, Kimmel PI. Is there an epidemic of HIV infection in the US ESRD program? J Am Soc Nephrol. 2004;15:2477–85.PubMedCrossRef

Schwartz EJ, Szczech LA, Ross MJ, Klotman ME, Winston JA, Klotman PE. Highly active antiretroviral therapy and the epidemic of HIV+ end-stage renal disease. J Am Soc Nephrol. 2005;16:2412–20.PubMedCrossRef

Lucas GM, Mehta SH, Atta MG, Kirk GD, Galai N, Vlahov D, et al. End-stage renal disease and chronic kidney disease in a cohort of African-American HIV-infected and at-risk HIV-seronegative participants followed between 1988 and 2004. AIDS. 2007;21:2435–43.PubMedCrossRef

Gardner LI, Holmberg SD, Williamson JM, Szczech LA, Carpenter CCJ, Rompalo AM, et al. Development of proteinuria or elevated serum creatinine and mortality in HIV-infected women. J Acquir Immune Defic Syndr. 2003;32:203–9.PubMedCrossRef

Palella FJ, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, et al. Mortality in the highly active antiretroviral therapy era Changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006;43:27–34.PubMedCrossRef

Cheung CY, Wong KM, Lee MP, Liu YL, Kwok H, Chung R, et al. Prevalence of chronic kidney disease in Chinese HIV-infected patients. Nephrol Dial Transplant. 2007;22:3186–90.PubMedCrossRef

10.

Yanagisawa N, Ando M, Ajisawa A, Imamura A, Suganuma A, Tsuchiya K, et al. Clinical characteristics of kidney disease in Japanese HIV-infected patients. Nephron Clin Pract. 2011;118:c285–91.PubMedCrossRef

11.

Mocroft A, Kirk O, Gatell J, Reiss P, Gargalianos P, Zilmer K, et al. Chronic renal failure among HIV-1-infected patients. AIDS. 2007;21:1119–27.PubMedCrossRef

12.

Fernando SK, Finkelstein FO, Moore BA, Weissman S. Prevalence of chronic kidney disease in an urban HIV infected population. Am J Med Sci. 2008;335:89–94.PubMedCrossRef

13.

Taal MW, Brenner BM. Predicting initiation and progression of chronic kidney disease: developing renal risk scores. Kidney Int. 2006;70:1694–705.PubMedCrossRef

14.

Yamagata K, Iseki K, Nitta K, Imai H, Iino Y, Matsuo S, et al. Chronic kidney disease perspectives in Japan and the importance of urinalysis screening. Clin Exp Nephrol. 2008;12:1–8.PubMedCrossRef

15.

Ripley E. Complementary effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in slowing the progression of chronic kidney disease. Am Heart J. 2009;157(6 Suppl):S7–16.PubMedCrossRef

16.

Gansevoort RT, Bakker SJL, de Jong PE. Early detection of progressive chronic kidney disease: is it feasible? J Am Soc Nephrol. 2006;17:1218–20.PubMedCrossRef

17.

Chen N, Hsu CC, Yamagata K, Langham R. Challenging chronic kidney disease: experience from chronic kidney disease prevention programs in Shanghai, Japan, Taiwan and Australia. Nephrology. 2010;15(Suppl 2):31–6.PubMedCrossRef

18.

Peralta CA, Shlipak MG, Judd S, Cushman M, McClellan W, Zakai NA, et al. Detection of chronic kidney disease with creatinine, cystatin C, and urine albumin-to-creatinine ratio and association with progression to end-stage renal disease and mortality. JAMA. 2011;305:1545–52.PubMedCrossRef

19.

Tokars JI, Frank M, Alter MJ, Arduino MJ. National surveillance of dialysis-associated disease in the United States, 2000. Semin Dial. 2002;15:162–71.PubMedCrossRef

20.

US Renal Data System. USRDS 2007 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease; 2007.

21.

Stehman-Breen CO, Gillen D, Steffes M. Racial differences in early-onset renal disease among young adults: the coronary artery risk development in young adults (CARDIA) study. J Am Soc Nephrol. 2003;14:2352–7.PubMedCrossRef

22.

Rao TK, Filippone EJ, Nicastri AD. Associated focal and segmental glomerulosclerosis in the acquired immunodeficiency syndrome. N Engl J Med. 1984;310:669–73.PubMedCrossRef

23.

Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12.PubMed

24.

Szczech LA, Hoover DR, Feldman JG, Cohen MH, Gange SJ, Gooze L, et al. Association between renal disease and outcomes among HIV-infected women receiving or not receiving antiretroviral therapy. Clin Infect Dis. 2004;39:1199–206.PubMedCrossRef

25.

Szczech LA, Gange SJ, van der Horst C, Bartlett JA, Young M, Cohen MH, et al. Predictors of proteinuria and renal failure among women with HIV infection. Kidney Int. 2002;61:195–202.PubMedCrossRef

26.

Gupta SK, Mamlin BW, Johnson CS, Dollins MD, Topf JM, Dube MP. Prevalence of proteinuria and the development of chronic disease in HIV-infected patients. Clin Nephrol. 2004;61:1–6.PubMed

27.

Fulop T, Olivier J, Meador RS, Hall J, Islam N, Henderson H, et al. Screening for chronic disease in the ambulatory HIV population. Clin Nephrol. 2010;73:190–6.PubMed

28.

Wyatt CM, Winston JA, Malvestutto DM, Fishbein DA, Barash I, Cohen AJ, et al. Chronic kidney disease in HIV infection: an urban epidemic. AIDS. 2007;21:2101–3.PubMedCrossRef

29.

Baekken M, Os I, Sandvik L, Oektedalen O. Microalbuminuria associated with indicators of inflammatory activity in an HIV-positive population. Nephrol Dial Transplant. 2008;23:3130–7.PubMedCrossRef

30.

Szczech LA, Grunfeld C, Scherzer R, Canchola JA, van der Horst C, Sidney S, et al. Microalbuminuria in HIV infection. AIDS. 2007;21:1003–9.PubMedCrossRef

31.

Lucas GM, Eustace JA, Sozio S, Mentari EK, Appiah KA, Moore RD. Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: a 12-year cohort study. AIDS. 2004;18:541–6.PubMedCrossRef

32.

Ross MJ, Klotman PE. Recent progress in HIV-associated nephropathy. J Am Soc Nephrol. 2002;13:2997–3004.PubMedCrossRef

33.

Han TM, Naicker S, Ramdial PK, Assounga AG. A cross-sectional study of HIV-seropositive patients with varying degrees of proteinuria in South Africa. Kidney Int. 2006;69:2243–50.PubMedCrossRef

34.

Post FA, Campbell LJ, Hamzah L, Collins L, Jones R, Siwani R, et al. Predictors of renal outcome in HIV-associated nephropathy. Clin Infect Dis. 2008;46:1282–9.PubMedCrossRef

35.

Freedman BI, Soucie JM, Stone SM, Pegram S. Familial clustering of end-stage renal disease in blacks with HIV-associated nephropathy. Am J Kidney Dis. 1999;34:254–8.PubMedCrossRef

36.

Szczech LA, Gupta SK, Habash R, Guasch A, Kalayjian R, Appel R, et al. The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection. Kidney Int. 2004;66:1145–52.PubMedCrossRef

37.

Centers for Disease Control and Prevention. Racial/ethnic disparities in prevalence, treatment, and control of hypertension-United States, 1999–2002. MMWR Morbid Mortal Wkly Rep. 2005;54:7–9.

38.

Franceschini N, Napravnik S, Eron JJ Jr, Szczech LA, Finn WF. Incidence and etiology of acute renal failure among ambulatory HIV-infected patients. Kidney Int. 2005;67:1526–31.PubMedCrossRef

39.

Wyatt CM, Arons RR, Klotman PE, Klotman ME. Acute renal failure in hospitalized patients with HIV: risk factors and impact on in-hospital mortality. AIDS. 2006;20:561–5.PubMedCrossRef

40.

Vallet-Pichard A, Pol S. Natural history and predictors of severity of chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection. J Hepatol. 2006;44(1 Suppl):S28–34.PubMedCrossRef

41.

Liangpunsakul S, Chalasani N. Relationship between hepatitis C and microalbuminuria: results from the NHANES III. Kidney Int. 2005;67:285–90.PubMedCrossRef

42.

Tsui JI, Vittinghoff E, Shlipak MG, O’Hare AM. Relationship between hepatitis C and chronic kidney disease: results from the third national health and nutrition examination survey. J Am Soc Nephrol. 2006;17:1168–74.PubMedCrossRef

43.

Daugas E, Rougier J-P, Hill G. HAART-related nephropathies in HIV-infected patients. Kidney Int. 2005;67:393–403.PubMedCrossRef

44.

Izzedine H, Harris M, Perazella M. The nephrotoxic effect of HAART. Nat Rev Nephrol. 2009;5:563–73.PubMedCrossRef

45.

Izzedine H, Hulot JS, Vittecoq D, Gallant JE, Staszewski S, Launay-Vacher V, et al. Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study. Nephrol Dial Transplant. 2005;20:743–6.PubMedCrossRef

46.

Arribas JR, Pozniak AL, Gallant JE, Dejesus E, Gazzard B, Campo RE, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naïve patients: 144-week analysis. J Acquir Immune Defic Syndr. 2008;47:74–8.PubMedCrossRef

47.

Jones R, Stebbing J, Nelson M, Moyle G, Bower M, Mandalia S, et al. Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case–control study. J Acquir Immune Defic Syndr. 2004;37:1489–95.PubMedCrossRef

48.

Gallant JE, Parish MA, Keruly JC, Moore RD. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis. 2005;40:1194–8.PubMedCrossRef

49.

Gallant JE, Moore RD. Renal function with use of a tenofovir-containing initial antiretroviral regimen. AIDS. 2009;23:1971–5.PubMedCrossRef

50.

Zimmermann AE, Pizzoferrato T, Bedford J, Morris A, Hoffman R, Broden G. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis. 2006;42:283–90.PubMedCrossRef

51.

Goicoechea M, Liu S, Best B, Sun S, Jain S, Kemper C, et al. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis. 2008;197:102–8.PubMedCrossRef

52.

Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systemic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis. 2010;51:496–505.PubMedCrossRef

53.

Siedner MJ, Atta MG, Lucas GM, Perazella MA, Fine DM. Poor validity of urine dipstick as a screening tool for proteinuria in HIV-positive patients. J Acquir Immune Defic Syndr. 2008;47:261–3.PubMedCrossRef

54.

Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. National kidney foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139:137–47.PubMed

55.

Ando M, Yanagisawa N, Ajisawa A, Tsuchiya K, Nitta K. Urinary albumin excretion within the normal range is an independent risk for near-term development of kidney disease in HIV-infected patients. Nephrol Dial Transplant. 2011;26:3923–9.

56.

Marras D, Bruggbman LA, Gao F. Replication and compartmentalization of HIV-1 in kidney epithelium of patients with HIV-associated nephropathy. Nat Med. 2002;8:522–6.PubMedCrossRef

57.

Kabanda A, Vandercam B, Bernard A, Lauwerys R, van Ypersele de Strihou CY. Low molecular weight proteinuria in human immunodeficiency virus-infected patients. Am J Kidney Dis. 1996;27:803–8.PubMedCrossRef

58.

Gatanaga H, Tachikawa N, Kikuchi Y, Teruya K, Genka I, Honda M, et al. Urinary β2-microglobulin as a possible sensitive marker for renal injury caused by tenofovir disoproxil fumarate. AIDS Res Hum Retrovir. 2006;22:744–8.PubMedCrossRef

59.

Kinai EI, Hanabusa H. Progressive renal tubular dysfunction associated with long-term use of tenofovir DF. AIDS Res Hum Retrovir. 2009;25:387–94.PubMedCrossRef

60.

Labarga P, Barreiro P, Martin-Carbonero L, Rodrigez-Novoa S, Solera C, Medrano J, et al. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS. 2009;23:1–8.CrossRef

61.

Hall AM, Edwards SG, Lapsley M, Connolly JO, Chetty K, O’Farrell S, et al. Subclinical tubular injury in HIV-infected individuals on antiretroviral therapy: a cross-sectional analysis. Am J Kidney Dis. 2099;54:1034–42.

62.

Jaafar A, Seronie-Vivien S, Malard L, Massip P, Chatelut E, Tack I. Urinary cystatin C can improve the renal safety follow-up of tenofovir-treated patients. AIDS. 2009;23:257–9.PubMedCrossRef

63.

Paragas N, Nickolas TL, Wyatt C, Foster CS, Sise M, Morgello S, et al. Urinary NGAL marks cystic disease in HIV-associated nephropathy. J Am Soc Nephrol. 2009;20:1687–92.PubMedCrossRef

64.

Ando M, Yanagisawa N, Ajisawa A, Tsuchiya, Nitta K. Kidney tubular damage in the absence of glomerular defects in HIV-infected patients on highly active antiretroviral therapy. Nephrol Dial Transplant. 2011;26:3224–9.

65.

Ando M, Yanagisawa N, Ajisawa A, Tsuchiya K, Nitta K. A simple model for predicting incidence of chronic kidney disease in HIV-infected patients. Clin Exp Nephrol. 2011;15:242–7.PubMedCrossRef

66.

Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145:247–54.PubMed

67.

Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.PubMedCrossRef

68.

Imai E, Horio M, Watanabe T, Iseki K, Yamagata K, Hara S, et al. Prevalence of chronic kidney disease in the Japanese general population. Clin Exp Nephrol. 2009;13:621–30.PubMedCrossRef

69.

Horio M, Imai E, Yasuda Y, Watanabe T, Matsuo S. Modification of the CKD epidemiology collaboration (CKD-EPI) equation for Japanese: accuracy and use for population estimates. Am J Kidney Dis. 2010;56:32–8.PubMedCrossRef

70.

Shlipak MG, Wassel Fyr CL, Chertow GM, Harris TB, Kritchevsky SB, Tylavsky FA, et al. Cystatin C and mortality risk in the elderly: the health, aging, and body composition study. J Am Soc Nephrol. 2006;17:254–61.PubMedCrossRef

71.

Kottgen A, Selvin E, Stevens LA, Levey AS, Van Lente F, Coresh J. Serum cystatin C in the United States: the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis. 2008;51:385–94.PubMedCrossRef

72.

Stevens LA, Coresh J, Schmid CH, Feldman HI, Froissart M, Kusek J, et al. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis. 2008;51:395–406.PubMedCrossRef

73.

Odden MC, Scherzer R, Bacchetti P, Szczech LA, Sidney S, Grunfeld C, et al. Cystatin C level as a marker of kidney function in human immunodeficiency virus infection: the FRAM study. Arch Intern Med. 2007;167:2213–9.PubMedCrossRef

74.

Knight EL, Verhave JC, Spiegelman D, Hillege HL, Zeeuw DD, Curhan GC, et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int. 2004;65:1416–21.PubMedCrossRef

75.

Mauss S, Berger F, Kuschak D, Henke J, Hegener P, Wolf E, et al. Cystatin C as a marker of renal function is affected by HIV replication leading to an underestimation of kidney function in HIV patients. Antivir Ther. 2008;13:1091–5.PubMed

76.

Barraclough K, Er L, Ng F, Harris M, Montaner J, Levin A. A comparison of the predictive performance of different methods of kidney function estimation in a well characterized HIV-infected population. Nephron Clin Pract. 2009;111:c39–48.PubMedCrossRef

77.

Stevens LA, Schmid CH, Greene T, Li L, Beck GJ, Joffe MM, et al. Factors other than glomerular filtration rate affect serum cystatin C levels. Kidney Int. 2009;75:652–60.PubMedCrossRef

78.

Tabatabai S, Sperati CJ, Atta MG, Janjua K, Toxbury C, Lucas GM, et al. Predictors of complication after percutaneous ultrasound-guided kidney biopsy in HIV-infected individuals: possible role of hepatitis C and HIV co-infection. Clin J Am Soc Nephrol. 2009;4:1766–73.PubMedCrossRef

79.

Hammer SM, Eron JJ Jr, Reiss P, Schooley RT, Thompson MA, Walmsley S, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA. 2008;300:555–70.PubMedCrossRef

80.

Eustace JA, Nuermberger E, Choi M, Scheel PJ Jr, Moore R, Briggs WA. Cohort study of the treatment of severe HIV-associated nephropathy with corticosteroids. Kidney Int. 2000;58:1253–60.PubMedCrossRef

81.

Wei A, Burns GC, Williams BA, Mohammed NB, Visintainer P, Sivak SL. Long-term survival in HIV-associated nephropathy with angiotensin-converting enzyme inhibition. Kidney Int. 2003;64:1462–71.PubMedCrossRef

82.

Choi AI, Rodriguez RA, Bacchetti P, Volberding PA, Havlir D, Bertenthal D, et al. Low rates of antiretroviral therapy among HIV-infected patients with chronic kidney disease. Clin Infect Dis. 2007;45:1633–9.PubMedCrossRef

83.

Gazzaruso C, Bruno R, Gazaniti A. Hypertension among HIV patients: prevalence and relationships to insulin resistance and metabolic syndrome. J Hypertens. 2003;21:1377–82.PubMedCrossRef

Title: How to manage HIV-infected patients with chronic kidney disease in the HAART era
Authors: Minoru Ando
Ken Tsuchiya
Kosaku Nitta
Publication date: 01-06-2012
Publisher: Springer Japan
Published in: Clinical and Experimental Nephrology / Issue 3/2012
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI: https://doi.org/10.1007/s10157-012-0585-7

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2012

Serum albumin level accurately reflects antioxidant potentials in idiopathic nephrotic syndrome

A case of monoclonal immunoglobulin G1-lambda deposition associated with membranous feature in a patient with hepatitis C viral infection

The relationship between the soluble Klotho protein and the residual renal function among peritoneal dialysis patients

Relationship between serum cystatin C and serum adiponectin level in type 2 diabetic patients

The impact of ferritin fluctuations on stable hemoglobin levels in hemodialysis patients

A rare case of acute kidney injury associated with autoimmune hemolytic anemia and thrombocytopenia after long-term usage of oxaliplatin

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials